Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT06769256
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Registry
-
NCT06769256
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06769256. Randomized; single masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2027-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
- Acronym
- H2-THROMBUS
- Condition
- ST-segment Elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- rhTNK-tPA, 4-8 mg
- Intervention (Drug)
- Tirofiban
- Lead sponsor
- Henan Institute of Cardiovascular Epidemiology
Record details
- Record id
cardio:ct-nct06769256- Content hash
fa4e25ea16093b00435007a717553c798b9d114c1d4a333642fd317502784068